Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203004 | 1.00 | SMARCA2 (0.49) | SMARCA2SMARCA4PBRM1ABCB1HRH4 | |
| SCHEMBL3998706 | 0.86 | HRH4 (0.49) | HRH4HRH3 | |
| SCHEMBL3197606 | 0.83 | HRH4 (0.61) | SMARCA2SMARCA4PBRM1HRH4GPR119 | |
| SCHEMBL3190194 | 0.81 | HRH4 (0.61) | HRH4HRH3 | |
| SCHEMBL3209109 | 0.80 | MAP4K4 (0.52) | HRH4HRH3 | |
| SCHEMBL3195553 | 0.79 | MAP4K4 (0.53) | HRH4HRH3 | |
| SCHEMBL3200673 | 0.79 | MAP4K4 (0.53) | HRH4HRH3 | |
| SCHEMBL3200455 | 0.78 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL3211051 | 0.78 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL3209101 | 0.76 | ALDH1A1 (0.41) | SMARCA2SMARCA4PBRM1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | SMARCA2 3437/4885SMARCA4 3037/4885PBRM1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.